Teladoc Stock Sinks as Wall Street Turns Cautious

Teladoc ( (TDOC) ) has fallen by -13.38%. Read on to learn why.

Teladoc shares fell 13.38% over the past week as a wave of cautious analyst updates reinforced investor concerns about growth and profitability. Several major Wall Street firms – including Evercore ISI, Stifel Nicolaus and Bank of America – all reiterated Hold ratings on the stock, with relatively low price targets clustered around $7.50 to $9.00. While Goldman Sachs has maintained a Buy rating, the broader consensus remains firmly neutral, signaling that analysts see limited near‑term upside.

The cautious stance is rooted in Teladoc’s latest quarterly results, which showed revenue slipping to $626.44 million from $640.51 million a year earlier, alongside a widening GAAP net loss of $49.51 million versus $33.28 million previously. That combination of flat-to-declining sales and persistent losses has made investors more skeptical about the company’s path to sustainable profitability in the competitive digital health and telemedicine market. As a result, even modest downgrades to price targets from banks like Citi, Goldman Sachs and BofA have carried extra weight.

For market watchers, Teladoc has become a classic “show me” story: analysts acknowledge some long-term potential but see enough headwinds to keep ratings at Hold for now. The drop in the share price reflects growing impatience with the lack of clear earnings progress, despite the company’s scale and brand recognition in virtual care. Unless Teladoc can stabilize revenue and narrow its losses in upcoming quarters, the stock may continue to trade under pressure, with sentiment driven largely by incremental analyst moves and any signs of a turnaround in its core business metrics.